All TreatGx users now have access to the updated Crohn’s disease treatment algorithm.
Crohn’s Disease
This comprehensive update incorporates information from AGA 2021[1] and ACG 2018[2] to help clinicians personalize treatment for their patients.
A key update to this algorithm is the restructuring of therapy streams to allow patients and healthcare providers to select the safest and most effective medications. Based on the clinical guideline and evidence review, Natalizumab was also removed as their routine use is no longer supported by the published evidence. Additional prescribing information and warning banners have been included, and indications for off-label use of drugs have been made more transparent to better help guide your selection.
As always, this update includes the TreatGx standard of providing personalized dosing based on pharmacogenetics, kidney function, liver function, and drug interactions.
References
- Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, Terdiman JP, Sultan S, Cohen BL, Chachu K et al: AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease. Gastroenterology 2021, 160(7):2496-2508.
- Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE: ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am J Gastroenterol 2018, 113(4):481-517.